Rho kinase inhibition in diabetic nephropathy

Radko Komers

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose of review: The Rho GTPases and their downstream effectors Rho-associated kinases (ROCKs) appear to be the molecules that converge numerous pathophysiological signals triggered by the diabetic milieu and represent promising molecular targets for nephroprotective treatment in diabetes. The review discusses recent studies exploring the consequences of diabetes-induced Rho-ROCK activation in the kidney and the effects of ROCK inhibition (ROCKi) in experimental diabetic nephropathy. Recent findings: Recent studies in models of type 1 and type 2 diabetes have indicated blood-pressureindependent nephroprotective actions of ROCKi in diabetic nephropathy. The underlying mechanisms include attenuation of diabetes-induced increases in renal expression of prosclerotic cytokines and extracellular matrix, resulting in slower development of glomerulosclerosis and interstitial fibrosis. The studies have also shown antiproteinuric affects of ROCKi that could be related to reductions in permeability of glomerular barri and beneficial effects on podocytes. Moreover hemodynamic mechanisms might be also involved. Summary: Despite remaining questions in this field, such as the specificity of currently available ROCKi, or the roles of individual ROCK isoforms, recent evidence in experimental diabetes, together with evidence generated in models of nondiabetic kidney disease and in clinical studies in patients with various cardiovascular disorders, suggest that ROCKi might in future broaden the spectrum of treatments available for patients with diabetic nephropathy.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume20
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

rho-Associated Kinases
Diabetic Nephropathies
Kidney
Podocytes
rho GTP-Binding Proteins
Kidney Diseases
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Extracellular Matrix
Permeability
Protein Isoforms
Fibrosis
Hemodynamics
Inhibition (Psychology)
Cytokines
Therapeutics

Keywords

  • Diabetic nephropathy
  • Fasudil
  • Rho-associated kinase

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Rho kinase inhibition in diabetic nephropathy. / Komers, Radko.

In: Current Opinion in Nephrology and Hypertension, Vol. 20, No. 1, 01.2011, p. 77-83.

Research output: Contribution to journalArticle

@article{e308c16f9f8642a7b88a2d1fe331fe56,
title = "Rho kinase inhibition in diabetic nephropathy",
abstract = "Purpose of review: The Rho GTPases and their downstream effectors Rho-associated kinases (ROCKs) appear to be the molecules that converge numerous pathophysiological signals triggered by the diabetic milieu and represent promising molecular targets for nephroprotective treatment in diabetes. The review discusses recent studies exploring the consequences of diabetes-induced Rho-ROCK activation in the kidney and the effects of ROCK inhibition (ROCKi) in experimental diabetic nephropathy. Recent findings: Recent studies in models of type 1 and type 2 diabetes have indicated blood-pressureindependent nephroprotective actions of ROCKi in diabetic nephropathy. The underlying mechanisms include attenuation of diabetes-induced increases in renal expression of prosclerotic cytokines and extracellular matrix, resulting in slower development of glomerulosclerosis and interstitial fibrosis. The studies have also shown antiproteinuric affects of ROCKi that could be related to reductions in permeability of glomerular barri and beneficial effects on podocytes. Moreover hemodynamic mechanisms might be also involved. Summary: Despite remaining questions in this field, such as the specificity of currently available ROCKi, or the roles of individual ROCK isoforms, recent evidence in experimental diabetes, together with evidence generated in models of nondiabetic kidney disease and in clinical studies in patients with various cardiovascular disorders, suggest that ROCKi might in future broaden the spectrum of treatments available for patients with diabetic nephropathy.",
keywords = "Diabetic nephropathy, Fasudil, Rho-associated kinase",
author = "Radko Komers",
year = "2011",
month = "1",
doi = "10.1097/MNH.0b013e32834131f8",
language = "English (US)",
volume = "20",
pages = "77--83",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Rho kinase inhibition in diabetic nephropathy

AU - Komers, Radko

PY - 2011/1

Y1 - 2011/1

N2 - Purpose of review: The Rho GTPases and their downstream effectors Rho-associated kinases (ROCKs) appear to be the molecules that converge numerous pathophysiological signals triggered by the diabetic milieu and represent promising molecular targets for nephroprotective treatment in diabetes. The review discusses recent studies exploring the consequences of diabetes-induced Rho-ROCK activation in the kidney and the effects of ROCK inhibition (ROCKi) in experimental diabetic nephropathy. Recent findings: Recent studies in models of type 1 and type 2 diabetes have indicated blood-pressureindependent nephroprotective actions of ROCKi in diabetic nephropathy. The underlying mechanisms include attenuation of diabetes-induced increases in renal expression of prosclerotic cytokines and extracellular matrix, resulting in slower development of glomerulosclerosis and interstitial fibrosis. The studies have also shown antiproteinuric affects of ROCKi that could be related to reductions in permeability of glomerular barri and beneficial effects on podocytes. Moreover hemodynamic mechanisms might be also involved. Summary: Despite remaining questions in this field, such as the specificity of currently available ROCKi, or the roles of individual ROCK isoforms, recent evidence in experimental diabetes, together with evidence generated in models of nondiabetic kidney disease and in clinical studies in patients with various cardiovascular disorders, suggest that ROCKi might in future broaden the spectrum of treatments available for patients with diabetic nephropathy.

AB - Purpose of review: The Rho GTPases and their downstream effectors Rho-associated kinases (ROCKs) appear to be the molecules that converge numerous pathophysiological signals triggered by the diabetic milieu and represent promising molecular targets for nephroprotective treatment in diabetes. The review discusses recent studies exploring the consequences of diabetes-induced Rho-ROCK activation in the kidney and the effects of ROCK inhibition (ROCKi) in experimental diabetic nephropathy. Recent findings: Recent studies in models of type 1 and type 2 diabetes have indicated blood-pressureindependent nephroprotective actions of ROCKi in diabetic nephropathy. The underlying mechanisms include attenuation of diabetes-induced increases in renal expression of prosclerotic cytokines and extracellular matrix, resulting in slower development of glomerulosclerosis and interstitial fibrosis. The studies have also shown antiproteinuric affects of ROCKi that could be related to reductions in permeability of glomerular barri and beneficial effects on podocytes. Moreover hemodynamic mechanisms might be also involved. Summary: Despite remaining questions in this field, such as the specificity of currently available ROCKi, or the roles of individual ROCK isoforms, recent evidence in experimental diabetes, together with evidence generated in models of nondiabetic kidney disease and in clinical studies in patients with various cardiovascular disorders, suggest that ROCKi might in future broaden the spectrum of treatments available for patients with diabetic nephropathy.

KW - Diabetic nephropathy

KW - Fasudil

KW - Rho-associated kinase

UR - http://www.scopus.com/inward/record.url?scp=79851508434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851508434&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e32834131f8

DO - 10.1097/MNH.0b013e32834131f8

M3 - Article

VL - 20

SP - 77

EP - 83

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 1

ER -